ACP
KNSA icon

Altitude Crest Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Altitude Crest Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-400,441
Closed -$7.9M – 18
2024
Q1 		$7.9M Sell
400,441
-55,600
-12% -$1.09M 3.38% 9
2023
Q4 		$8M Buy
+456,041
New +$7.5M 5.35% 8

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altitude Crest Partners's KNSA Position: Q2 2024 in Review

Altitude Crest Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2024, closing a stake of 400,441 shares — an estimated $7.9M sold.

Altitude Crest Partners first reported a position in KNSA in Q4 2023 and held it in 2 quarters. The position peaked at $8M in Q4 2023. 132 funds tracked by Wall St. Rank hold KNSA as of Q2 2024.

  • Altitude Crest Partners reported no remaining Kiniksa Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 400,441 Kiniksa Pharmaceuticals shares in Q2 2024, an estimated $7.9M.
  • Altitude Crest Partners first reported a position in Kiniksa Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Altitude Crest Partners's Kiniksa Pharmaceuticals position peaked at $8M in Q4 2023.
  • 132 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.